Using low dose colchicine to reduce vascular risks in patients with peripheral artery disease.
2/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)
This study is looking at whether a low dose of colchicine can help people with peripheral artery disease (PAD) by reducing the risk of serious heart and leg problems, and we're inviting 1,000 participants from the U.S. to join in and see how it works compared to a placebo.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10982434 on NIH RePORTER |
What this research studies
This research investigates the effects of low dose colchicine on patients with peripheral artery disease (PAD) through a randomized, double-blind, placebo-controlled trial. The study aims to enroll 1,000 participants from the U.S. as part of a larger multinational effort involving 6,150 participants. By targeting inflammation with colchicine, the research seeks to determine if this treatment can lower the risk of serious cardiovascular and limb-related complications. Participants will be monitored closely to assess the outcomes of the treatment compared to a placebo.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with peripheral artery disease who are at risk for cardiovascular complications.
Not a fit: Patients without a diagnosis of peripheral artery disease or those who are not at risk for cardiovascular events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of cardiovascular events and improve the quality of life for patients with peripheral artery disease.
How similar studies have performed: Previous studies have shown that colchicine can reduce cardiovascular risks in patients with coronary disease, indicating potential for success in this novel application.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Vemulapalli, Sreekanth — Duke University
- Study coordinator: Vemulapalli, Sreekanth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.